Increased Immunoglobulin Gamma-3 Chain C in the Serum, Saliva, and Urine of Patients with Systemic Lupus Erythematosus.

Immunoglobulin gamma-3 chain C (IGHG3) levels have been detected in the blood and tissue of patients with systemic lupus erythematosus (SLE). This study aims to assess its clinical value by measuring and comparing levels of IGHG3 in different body fluids in patients with SLE. The levels of IGHG3 in saliva, serum, and urine from 181 patients with SLE and 99 healthy controls were measured and analyzed. In patients with SLE and healthy controls, salivary IGHG3 levels were 3078.9 ± 2473.8 and 1413.6 ± 1075.3 ng/mL, serum IGHG3 levels were 478.1 ± 160.9 and 364.4 ± 97.9 μg/mL, and urine IGHG3 levels were 64.0 ± 74.5 and 27.1 ± 16.2 ng/mL, respectively (all < 0.001). Salivary IGHG3 was correlated with ESR (correlation coefficient [r], 0.173; = 0.024). Serum IGHG3 was correlated with leukocyte count (r, -0.219; = 0.003), lymphocyte count (r, 0.22; = 0.03), anti-dsDNA antibody positivity (r, 0.22; = 0.003), and C3 levels (r, -0.23; = 0.002). Urinary IGHG3 was correlated with hemoglobin level (r, -0.183; = 0.021), ESR (r, 0.204; = 0.01), anti-dsDNA antibody positivity (r, 0.262; = 0.001), C3 levels (r, -0.202; = 0.011), and SLE disease activity index (r, 0.332; = 0.01). Urinary IGHG3 was higher in patients with nephritis than in those without (119.5 ± 110.0 vs. 49.8 ± 54.4 ng/mL; < 0.01). IGHG3 was increased in the saliva, serum, and urine of patients with SLE. While salivary IGHG3 was not identified to be specific to SLE disease activity, serum IGHG3 showed correlations with clinical characteristics. Urinary IGHG3 levels were associated with disease activity and renal involvement in SLE.